Project: First small molecule drug inhibitor of microRNAs: Treatment for systemic lupus erythematosus

Acronym BUTTERFLY (Reference Number: 12979)
Duration 01/04/2019 - 03/04/2022
Project Topic BUTTERFLY will deliver a first-in-class drug for the treatment of systemic lupus erythematosus (SLE). The BUTTERFLY drug will inhibit miR-155, and will be the first small molecule drug that directly targets microRNAs. To do so, BUTTERFLY partners will implement a unique drug discovery platform for the cost- and time-efficient development of new drugs. By the end of BUTTERFLY, the lead drug will have been validated in animal models and will be ready to enter final regulatory preclinical testing.
Network Eurostars 2
Call Eurostars Cut–off 10

Project partner

Number Name Role Country
1 Saverna Therpautics AG Coordinator Switzerland
2 SpiroChem AG Partner Switzerland
3 Redoxis AB Partner Sweden